Endpoints News
LightNews LightNews
banner
endpts.com
Endpoints News
@endpts.com
3.1K followers 600 following 1.1K posts
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Posts Replies Media Videos
Pinned
endpts.com
Endpoints News @endpts.com · Dec 17
Just finding us here? Endpoints News has a starter pack with our journalists so you can follow the team!
go.bsky.app/NzDRUhL
endpts.com
Neurocrine’s Ingrezza failed a Phase 3 trial in dyskinetic cerebral palsy, missing both primary and key secondary endpoints.
Neurocrine’s Ingrezza flunks pivotal study in dyskinetic cerebral palsy
Neurocrine's Ingrezza fails Phase 3 trial in dyskinetic cerebral palsy, missing endpoints for reducing chorea movements. Drug already approved for other conditions.
endpoints.news
December 23, 2025 at 7:03 PM
endpts.com
Exclusive: Boston startup Cellens pulled in $6.5M to develop a new bladder cancer test that reads the physical properties of cells.
Exclusive: Cellens raises $6.5M to advance physics-based test for bladder cancer
Cellens raises $6.5M for AI-physics bladder cancer detection platform, led by SOSV with Labcorp Venture Fund & others. Tech uses atomic force microscopy for cancer detection.
endpoints.news
December 23, 2025 at 4:52 PM
endpts.com
Pfizer reported a patient death linked to a thrombotic stroke in a Hympavzi hemophilia trial, but does not expect an impact on overall safety.
Updated: Pfizer discloses patient death in Hympavzi hemophilia trial
Pfizer reports death from thrombotic stroke in Hympavzi hemophilia trial patient who was receiving 150mg weekly dose and had hemophilia A with inhibitors
endpoints.news
December 23, 2025 at 3:14 PM
endpts.com
Windward pays up to $700M for Qyuns bispecific.
endpoints.news/windward-get...
Windward pays up to $700M to gain Qyuns bispecific in second China deal of year
Windward Bio acquires TSLP and IL-13 bispecific antibody from Qyuns Therapeutics in deal worth up to $700M, adding to portfolio of respiratory and dermatology drugs.
endpoints.news
December 22, 2025 at 9:40 PM
endpts.com
Shionogi will acquire one of the only approved ALS drugs for $2.5B.
endpoints.news/shionogi-wil...
Shionogi will pay $2.5B to acquire one of the only approved ALS drugs
Shionogi acquires ALS drug Radicava from Bain Capital-owned Tanabe Pharma in $2.5B deal. Drug is one of few FDA-approved treatments for ALS alongside riluzole and Biogen/Ionis' Qalsody.
endpoints.news
December 22, 2025 at 7:07 PM
endpts.com
Boston-based startup Aktis Oncology files for IPO.
endpoints.news/aktis-oncolo...
Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline
Aktis Oncology files for Nasdaq IPO under ticker
endpoints.news
December 22, 2025 at 4:38 PM
endpts.com
AstraZeneca bets up to $2B on Jacobio's pan-KRAS cancer inhibitor.
endpoints.news/astrazeneca-...
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer
AstraZeneca pays $100M upfront for Jacobio Pharma's JAB-23E73 cancer drug rights outside China; could pay $1.9B in milestones. Drug is in Phase 1 trials in US and China.
endpoints.news
December 22, 2025 at 3:37 PM
endpts.com
Aditum is partnering with Fosun in a major biobuck collaboration.
endpoints.news/joe-jimenezs...
Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration
Aditum Bio, the biotech company creation firm from former Novartis leaders Joe Jimenez and Mark Fishman, has returned to China for another deal.
endpoints.news
December 19, 2025 at 5:52 PM
endpts.com
WANTED: Your take on biopharma. Where do you think the industry is headed? Take our three-minute survey and be first to receive the Biopharma Sentiment Index results in January.
endpoints.news/endpoints-bi...
Take the Biopharma Sentiment Index survey for Q1 2026
Endpoints News seeks biopharma industry input for their Biopharma Sentiment Index (BPSI), a quarterly survey tracking biotech and pharma confidence and trends.
endpoints.news
December 19, 2025 at 3:36 PM
endpts.com
The new year is fast approaching, and with it #JPM26. We’ll host our annual event on Monday and Tuesday — and its going to be a good one. Read on for a sneak peak: endpoints.news/endpoints-at...
What Endpoints will be talking about at JPM: Major CEOs, top investors, China and more
Endpoints News previews JPM event in SF featuring interviews with Novo CEO Doustdar, GSK's Wood, Nobel Laureate Ramsdell, Hengrui's Jiang & others discussing pharma industry trends
endpoints.news
December 19, 2025 at 1:56 PM
endpts.com
China’s biotech sector could soon overtake the US, a national security commission has said.
endpoints.news/us-commissio...
China's biotech sector is advancing faster than thought, US commission says
US Congressional commission warns China may surpass US in biotech, urges swift action. Michelle Rozo, vice chair, notes progress on prior recommendations but says more needed to protect US interests.
endpoints.news
December 19, 2025 at 12:32 PM
Reposted by Endpoints News
jaredwhitlock.bsky.social
RFK Jr. adds conditions to newborn screening list, but future path unclear

endpoints.news/rfk-jr-adds-...
RFK Jr. adds conditions to newborn screening list, but future path unclear
HHS Secretary Robert F. Kennedy Jr. added metachromatic leukodystrophy and Duchenne to a federal newborn screening list, reviving efforts that had been stalled under the Trump administration — though ...
endpoints.news
December 17, 2025 at 6:38 PM
Reposted by Endpoints News
scienceboss.bsky.social
Addition Therapeutics raises $106.5M for all-RNA (no DNA required) gene insertion therapies based on retrotransposons, aka 'jumping genes'

Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for @endpts.com has the details: endpoints.news/addition-the...
Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies
Addition Therapeutics has raised $106.5 million for a new way to install therapeutic genes in the human genome.
endpoints.news
December 17, 2025 at 1:44 PM
endpts.com
Takeda reported Phase 3 wins for zasocitinib, the immunology drug it bought from Nimbus Therapeutics for $4B. endpoints.news/takedas-4b-i...
Takeda's $4B immunology drug achieves first Phase 3 successes
Takeda said Thursday that its drug zasocitinib succeeded in two Phase 3 studies for plaque psoriasis, comparing it to both placebo and Amgen’s Otezla.
endpoints.news
December 18, 2025 at 9:00 PM
endpts.com
🏆 Who won and who didn’t in 2025? 😮‍💨 Our annual Endpoints winners and losers list takes stock of the year across people, drugs and companies.
The Endpoints winners and losers list: Who was up and who was down in 2025
The 2025 list of biopharma's biggest winners and losers, chosen by Endpoints News staff.
endpoints.news
December 18, 2025 at 7:45 PM
endpts.com
Exclusive: Steve Paul is back, co-founding Syremis Therapeutics and raising $165M to pursue a next-gen schizophrenia drug following Karuna’s $14B exit.
Exclusive: Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis
Steve Paul is back with a fresh take on schizophrenia drugs, co-founding a new biotech called Syremis Therapeutics that’s already landed $165 million in a Series A, Endpoints News has learned.
endpoints.news
December 18, 2025 at 5:49 PM
endpts.com
Lilly’s obesity pill orforglipron is the first oral GLP-1 to prove it can maintain weight loss in Phase 3, carving out a new role for pills in obesity care.
Lilly’s obesity pill is the first oral GLP-1 to show its worth in the maintenance setting
Eli Lilly's oral obesity drug orforglipron helped maintain weight loss in patients who were previously on GLP-1 injections Wegovy and Zepbound.
endpoints.news
December 18, 2025 at 3:40 PM
endpts.com
Berkeley-based Addition Therapeutics raised $106.5M to develop all-RNA “jumping gene” therapies that could offer a nonviral alternative for gene insertion.
Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies
Addition Therapeutics has raised $106.5 million for a new way to install therapeutic genes in the human genome.
endpoints.news
December 17, 2025 at 8:58 PM
endpts.com
Several drugmakers are expected to announce new “most favored nation” pricing deals with the White House on Friday, according to sources.
Several companies expected to announce ‘most favored nation’ deals Friday at White House, sources say
White House to announce new drug pricing deals with pharma companies; Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk and EMD Serono have already made agreements
endpoints.news
December 17, 2025 at 7:43 PM
endpts.com
After years of model-building hype, AI biotechs are refocusing on molecules — with 2026 shaping up as a key test of whether AI can deliver real drugs.
Models are out, molecules are in as AI startups sprint to clinic
Many AI-focused biotechs are prioritizing creating molecules over building models, with 2026 set to be a key year of clinical activity.
endpoints.news
December 17, 2025 at 5:45 PM
endpts.com
Endpoints at #JPM26 is bringing together the leaders shaping what's next, including Fred Ramsdell, Nobel Laureate & Scientific Advisor at Sonoma Biotherapeutics, and Mike Doustdar, President & CEO of Novo Nordisk.

Join us in SF as we examine the big questions shaping 2026. Reserve your spot now.
Endpoints at #JPM25 - Biopharma’s Foundational Reset
Each new biopharma year doesn’t start on January 1 — it kicks off a few weeks later when leaders gather in San Francisco. The annual JPM event sets the tone for a year of dealmaking, and in 2026, lead...
events.endpoints.news
December 17, 2025 at 4:25 PM
endpts.com
Hansa’s enzyme therapy imlifidase failed a Phase 3 study in rare anti-GBM kidney disease, missing its primary endpoint after a strong control arm performance.
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease
Hansa Biopharma said Tuesday that its IgG-targeting treatment candidate has failed a late-stage study in a rare type of kidney disease due to an overperforming control arm.
endpoints.news
December 17, 2025 at 3:09 PM
endpts.com
Noom is planning to bring GLP-1s to non-obese patients with a new microdose offering.
endpoints.news
December 16, 2025 at 10:28 PM
endpts.com
A new California biotech wants to bring a niche pain drug, which has been approved in Italy for over a decade, to the US. Ambros has raised $125M, and they've got Vivek Ramaswamy on board.
Chronic pain biotech emerges with $125M and Vivek Ramaswamy on board
A California biotech launched on Tuesday morning to try to bring a niche pain drug, approved in Italy for more than a decade, to the US.
endpoints.news
December 16, 2025 at 6:48 PM
endpts.com
🎅 Post Ho-Ho-Hoc?🎅 Biotech is closing the year with a flurry of news, and this week we’re revealing our annual list of winners and losers. Join us on Thursday at 12pm ET for a special edition of Post Hoc Live as we go through every detail.
www.youtube.com/live/If7uddr...
Biopharma’s Winners and Losers of 2025
YouTube video by Endpoints News
www.youtube.com
December 16, 2025 at 5:01 PM